Systems Biology and Its Application in TCM Formulas Research presents a theoretical research system formed for Traditional Chinese Medicine (TCM) formulas, along with information on the study of Shexiang Baoxin Pill (SBP), a TCM formula that has shown significant clinical efficacy in the treatment of cardiovascular diseases. The content combines theory and practice, and includes guidance for both theoretical concepts and operable technical routes. This is a valuable source not only for biomedical researchers involved in Systems Biology studies, but also for students and scientists interested in learning more about Traditional Chinese Medicine and its applications in contemporary medicine.
- Explains, in detail, the Shexiang Baoxin Pill (SBP), a TCM formula efficiently applied in the treatment of cardiovascular diseases
- Presents TCM formulas from perspectives of systems biology, basic chemical material groups, modern pharmacology and network biology
- Offers an overview on biology, modern chemistry and information technology as applied in Systems Biology research
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Part I Modern Research Strategies and Methodologies of Traditional Chinese Medicine 1. Strategies on the Modern Research System for Traditional Chinese Medicine 2. Theories and methodology of the study on pharmacodynamics material basis of Traditional Chinese Medicine 3. Application of systems biology in the research of Traditional Chinese Medicine genome of yeast 4. Applications of Network Pharmacology in the Study of TCM Formulas 5. Applications of Intestinal Flora in the Study of TCM Formulas 6. A New Weapon of Traditional Chinese Medicines Research: Connectivity Map
Part II Modern Research of Shexiang Baoxin Pill (SBP) 7. Identification of Multiple Constituents in Shexiang Baoxin Pill by LC Coupled with DAD-ESI-MS-MS 8. Analysis of the Bioactive Constituents of Shexiang Baoxin Pill by Serum Pharmacochemistry 9. Quality Standard for Shexiang Baoxin Pill 10. Pharmacokinetic Study of Shexiang Baoxin Pill 11. Metabolomic study of Shexiang Baoxin Pill 12. Network Pharmacology Study of Shexiang Baoxin Pill
Prof. Wei-dong Zhang, doctoral supervisor, is assistant dean of School of Pharmacy of Second Military Medical University, professor of Cheung Kong Scholars program (MOE of China). He also served as member of the tenth session of the Chinese Pharmacopoeia Committee, vice-president of the Specialty Committee of Chinese Medicine Chemistry of Chinese Pharmaceutical Association, vice-president of the World Federation of Chinese Medicine Society, and expert of New Drug Review Committee of the State Food and Drug Administration. Prof. Zhang's major achievements were made in the field of bioactive natural products discovery for therapeutical applications, QA&QC of herbal medicine, biological fingerprint, formula of TCM, metabonomics and chemical biology of natural products. Prof. Zhang earned the National Prize for Progress in Science and Technology in 2010 and 2013, the National Outstanding Young Scientist Foundation of China in 2007, Qiushi Outstanding Youth Scientist Award in 2008. He has hosted 31 projects, including major projects of National Natural Science Foundation of China, face items of National Natural Science Foundation of China, the "863" national project, 'Significant New Drug Creation' of Project of Major National R& D Project, and the EU seventh framework of international cooperation in traditional Chinese medicine research, etc. By now Prof. Zhang has published more than 400 peer-reviewed papers in international scientific journals, including Science, Proceedings of the National Academy of Sciences of the United States of America, J. Am. Chem. Soc., Clin Cancer Res., Chemical Communications, Organic Letters, Briefings in Bioinformatics, Journal of Natural Products, Tetrohedron, Planta Medica, Journal of Chromatography A and Journal of Hepatology. He applied for 55 national invention patents, 46 of which has been authorized. He also applied for 7 International Invention Patents, of which 2 have entered the United States. 9 new drugs have earned certification or clinical approval.